CapsoVision, Inc
Close on Oct 19, 2026
- Market cap
- $333.08M
- P/E (TTM)
- –
- Dividend yield
- –
About CapsoVision
Electromedical & Electrotherapeutic Apparatus, SIC 3845
The company is a medical technology firm that develops diagnostic and screening products for identifying abnormalities in the gastrointestinal tract. Its principal commercial offering is the CapsoCam capsule endoscopy system, which includes the CapsoCam Plus single-use capsule that captures panoramic images with onboard storage, along with viewing software platforms known as CapsoCloud and CapsoView. The company is also developing the CapsoCam Colon capsule and auxiliary products such as a delivery device and a patency capsule. Its primary customers are gastroenterologists practicing in clinics and hospital settings.
Corporate headquarters are located in Saratoga, California. The company distributes its products domestically in the United States through a direct sales team, while serving international markets through internal sales personnel and independent distributors. Across its clinical and commercial operations, its small-bowel endoscopy capsule has been administered to more than 161,000 patients, and the business maintains an intellectual property portfolio consisting of more than 140 issued patents.
Summary of the business section of CapsoVision's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CapsoVision, Inc
- Founded
- 2005
- Headquarters
- Saratoga, CA
- Address
- 18805 Cox Avenue Suite 250 95070
- Phone
- (408) 370-4790
- Employees
- 99, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Santa Clara, California
Stock & identifiers
- Ticker
- CV
- Exchange
- Nasdaq
- IPO date
- Jul 3, 2025
- Shares outstanding
- 50M, Aug 12, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1378325
- CUSIP
- 140935107
- ISIN
- US1409351079
- LEI
- 529900I9VO18RX33ME31
- EIN
- 20-3369494
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kang-Huai Wang | See Remarks, Director | 721,732 |
| Douglas Patrick Atkinson | Head of Global Sales | 107,357 |
| David Michael Garcia | Sr. VP of Finance | – |
| Rebecca Ann Petersen | Director of Clinical Affairs | 24,834 |
| Kevin Michael Lundquist | Chief Financial Officer | – |
| David Stanley Shields | Director | 0 |
| Joanne Carol Imperial | Director | 1,687 |
| Hui Ying Kuo | Director | 15,263 |
| Julia S. Gouw | Director | 4,909 |
| Wen-Herng Henry King | Director | 25,619 |
| Michele Harari | Director | 61,065 |
| Chen Lung Tsai | Director | 120,385 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 3, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 13, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |